Life Biosciences doses first patient in Phase 1 trial
The trial targets age-related vision loss using their Epigenetic Restoration approach for optic neuropathies like glaucoma and NAION.
Latest Life Biosciences News & Updates
See the latest news and media coverage for Life Biosciences. We track all announcements, press releases, and industry mentions in real time, all in one place.
Biotechnology company developing cellular rejuvenation therapies
lifebiosciences.com- Headquarters
- Boston, United States
- Founded year
- 2017
- Company type
- Private company
- Number of employees
- 25–50
- Industry
- Biotechnology & Medical Research
Last updated
Latest news about Life Biosciences
In short: Life Biosciences reached a milestone by dosing the first patient in a Phase 1 trial of its cell-rejuvenating therapy for vision loss.
Company announcements
Life Biosciences dosed first patient in Phase 1 trial
The trial evaluates ER-100 for optic neuropathies including glaucoma and NAION, targeting root cause of age-related vision loss.
Life Biosciences features in TIME100 Companies list
The recognition highlights their work reversing age-related diseases via epigenetic reprogramming. They remain committed to advancing transformative science.
Life Biosciences secures $80 million Series D financing
Funding supports Phase 1 trial of ER-100 for optic neuropathies and advances Partial Epigenetic Reprogramming platform. Announced April 8, 2026.
Media coverage
World’s first cell‑rejuvenating therapy given to patient | Features | telegraphherald.com
The experimental treatment by Life Biosciences will deliver three distinct genetic edits to regenerate neurons in the optic nerve, which can be damaged in people...
Longevity medicine's do-or-die moment
If cell reprogramming is successful, it'll be a watershed moment in the study of aging.
World's first cell‑rejuvenating therapy given to patient
A Boston company treated its first patient with a therapy intended to allow aging optic nerve cells to behave as though they were young again...
Longevity Startup Doses First Human in Bid to Reverse Age-Related Sight Loss
The FDA recently approved the cellular rejuvenation therapy ER-100 for human clinical trials.
Never miss news about Life Biosciences
Track Life Biosciences and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Life Biosciences competitors & trending companies
Browse news for competitors to Life Biosciences and other trending companies.
Altos
NewLimit
Retro
VTX
AITX
Amrize
Advocate Health
Arconic
ARDG
Ashland
LB Pharmaceuticals
Gossamer Bio
USAR
Simpson Strong‑Tie
Celestica
Capricor
MediaAlpha
3D Systems
Generate:Biomedicines
FutureFuel
WisdomTree
Celeris
Coupang
LiveWire
Fermi
Science
Biglari Holdings Inc.
Pega
Global Self Storage
Utz
Humanoid
Diverzify
Openship
Taalas